2,376 reports of this reaction
1.2% of all CYCLOSPORINE reports
#19 most reported adverse reaction
OCULAR HYPERAEMIA is the #19 most commonly reported adverse reaction for CYCLOSPORINE, manufactured by Allergan, Inc.. There are 2,376 FDA adverse event reports linking CYCLOSPORINE to OCULAR HYPERAEMIA. This represents approximately 1.2% of all 190,279 adverse event reports for this drug.
Patients taking CYCLOSPORINE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a less commonly reported adverse event for CYCLOSPORINE, but still significant enough to appear in the safety profile.
In addition to ocular hyperaemia, the following adverse reactions have been reported for CYCLOSPORINE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 2,376 FDA reports for CYCLOSPORINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 1.2% of all adverse event reports for CYCLOSPORINE, making it a notable side effect.
If you experience ocular hyperaemia while taking CYCLOSPORINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.